These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Racial Differences in Treatment Decision-Making for Men with Clinically Localized Prostate Cancer: a Population-Based Study. Xu J; Janisse J; Ruterbusch J; Ager J; Schwartz KL J Racial Ethn Health Disparities; 2016 Mar; 3(1):35-45. PubMed ID: 26896103 [TBL] [Abstract][Full Text] [Related]
3. Men's perspectives on selecting their prostate cancer treatment. Xu J; Dailey RK; Eggly S; Neale AV; Schwartz KL J Natl Med Assoc; 2011 Jun; 103(6):468-78. PubMed ID: 21830629 [TBL] [Abstract][Full Text] [Related]
4. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371 [TBL] [Abstract][Full Text] [Related]
5. Patient Knowledge and Qualities of Treatment Decisions for Localized Prostate Cancer. Daum LM; Reamer EN; Ruterbusch JJ; Liu J; Holmes-Rovner M; Xu J J Am Board Fam Med; 2017; 30(3):288-297. PubMed ID: 28484061 [TBL] [Abstract][Full Text] [Related]
6. Active surveillance for low-risk localized prostate cancer: what do men and their partners think? Mallapareddi A; Ruterbusch J; Reamer E; Eggly S; Xu J Fam Pract; 2017 Feb; 34(1):90-97. PubMed ID: 28034917 [TBL] [Abstract][Full Text] [Related]
7. The psychological impact of being on a monitoring pathway for localised prostate cancer: A UK-wide mixed methods study. Matheson L; Wilding S; Wagland R; Nayoan J; Rivas C; Downing A; Wright P; Brett J; Kearney T; Cross W; Glaser A; Gavin A; Watson E Psychooncology; 2019 Jul; 28(7):1567-1575. PubMed ID: 31132801 [TBL] [Abstract][Full Text] [Related]
8. 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Volk RJ; McFall SL; Cantor SB; Byrd TL; Le YC; Kuban DA; Mullen PD Psychooncology; 2014 Apr; 23(4):467-72. PubMed ID: 24243777 [TBL] [Abstract][Full Text] [Related]
9. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297 [TBL] [Abstract][Full Text] [Related]
10. Racial Disparities in Active Surveillance for Prostate Cancer. Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691 [TBL] [Abstract][Full Text] [Related]
11. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. Goh AC; Kowalkowski MA; Bailey DE; Kazer MW; Knight SJ; Latini DM BJU Int; 2012 Jul; 110(2 Pt 2):E50-6. PubMed ID: 22145791 [TBL] [Abstract][Full Text] [Related]
12. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902 [TBL] [Abstract][Full Text] [Related]
13. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309 [TBL] [Abstract][Full Text] [Related]
14. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial. Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A; Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237 [TBL] [Abstract][Full Text] [Related]
15. Decision-making processes among men with low-risk prostate cancer: A survey study. Hoffman RM; Van Den Eeden SK; Davis KM; Lobo T; Luta G; Shan J; Aaronson D; Penson DF; Leimpeter AD; Taylor KL Psychooncology; 2018 Jan; 27(1):325-332. PubMed ID: 28612468 [TBL] [Abstract][Full Text] [Related]
16. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice. Herden J; Weissbach L World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583 [TBL] [Abstract][Full Text] [Related]
17. Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable-risk prostate cancer. Huang D; Ruan X; Huang J; Zhang N; Jiang G; Gao Y; Xu D; Na R Cancer Med; 2023 Apr; 12(8):9868-9878. PubMed ID: 36727535 [TBL] [Abstract][Full Text] [Related]
18. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. Chapple A; Ziebland S; Herxheimer A; McPherson A; Shepperd S; Miller R BJU Int; 2002 Aug; 90(3):257-64. PubMed ID: 12133062 [TBL] [Abstract][Full Text] [Related]
19. Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS). Xu J; Bock CH; Janisse J; Woo J; Cher ML; Ginsburg K; Yacoub R; Goodman M Cancer; 2024 May; 130(10):1797-1806. PubMed ID: 38247317 [TBL] [Abstract][Full Text] [Related]